Add Formweb to your mobile device
System Formulary Update
Bendamustine
Situation:
The bendamustine product standardization was approved by the System Pharmacy & Therapeutics Committee in November 2023.
Background:
The following medications were reviewed: bendamustine (Bendeka 100 mg/4 mL injection solution MDV, Belrapzo 100 mg/4 mL injection solution MDV, Treanda 25 mg powder for solution (for reconstitution) SDV (associated generics), Treanda 100 mg powder for solution (for reconstitution) SDV (associated generics), Vivimusta 100 mg/4 mL injection solution MDV)
Assessment/Recommendations:
System P&T voted to include the following product from the UNC Health Medication Formulary:
- Bendamustine (Bendeka) 100 mg/4 mL injection solution MDV
- Bendamustine orders must be signed by a Hematology/Oncology Attending Physician
System P&T voted to exclude the following products on the UNC Health Care System Drug Formulary:
- Bendamustine (Belrapzo) 100 mg/4 mL injection solution MDV
- Bendamustine (Treanda) 25 mg powder for solution (for reconstitution) SDV (associated generics)
- Bendamustine (Treanda) 100 mg powder for solution (for reconstitution) SDV (associated generics)
- Vivimusta 100 mg/4 mL injection solution MDV
Note: Stock of this formulary product may vary at individual entities
Formulary/Epic Changes will Go-Live on Tuesday, December 19, 2023